Literature DB >> 19017950

The Erk2 MAPK regulates CD8 T cell proliferation and survival.

Warren N D'Souza1, Chiung-Fang Chang, April M Fischer, Manqing Li, Stephen M Hedrick.   

Abstract

The magnitude of T cell responses is determined by proliferation and survival decisions made by the responding cells. We now demonstrate that the Erk MAPK pathway plays a critical role in these cell fate decisions within CD8 T cells. While Erk1 is dispensable for all aspects of CD8 T cell activation, Erk2 is required for the proliferation of CD8 T cells activated in the absence of costimulation. Surprisingly, Erk2 is not required for proliferation following the addition of a costimulatory signal in vitro, or upon viral infection in vivo, but regulates the size of the responding population by enhancing cell survival. An important component of this Erk2-derived signal is the transcriptional regulation of Bcl-2 family members Bcl-x(L) and Bim, and impaired Erk2-deficient CD8 T cell survival can be rescued by genetic ablation of Bim. These studies ascribe multifaceted functions specific to Erk2 in CD8 T cell activation, proliferation, and survival.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19017950      PMCID: PMC2847891          DOI: 10.4049/jimmunol.181.11.7617

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  65 in total

1.  Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation.

Authors:  M J van Stipdonk; E E Lemmens; S P Schoenberger
Journal:  Nat Immunol       Date:  2001-05       Impact factor: 25.606

2.  Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells.

Authors:  S M Kaech; R Ahmed
Journal:  Nat Immunol       Date:  2001-05       Impact factor: 25.606

Review 3.  MAP kinases in the immune response.

Authors:  Chen Dong; Roger J Davis; Richard A Flavell
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

4.  Cutting edge: antigen-independent CD8 T cell proliferation.

Authors:  P Wong; E G Pamer
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

Review 5.  The Ras/MAPK cascade and the control of positive selection.

Authors:  José Alberola-Ila; Gabriela Hernández-Hoyos
Journal:  Immunol Rev       Date:  2003-02       Impact factor: 12.988

6.  RasGRP is essential for mouse thymocyte differentiation and TCR signaling.

Authors:  N A Dower; S L Stang; D A Bottorff; J O Ebinu; P Dickie; H L Ostergaard; J C Stone
Journal:  Nat Immunol       Date:  2000-10       Impact factor: 25.606

7.  Regulation of the helix-loop-helix proteins, E2A and Id3, by the Ras-ERK MAPK cascade.

Authors:  G Bain; C B Cravatt; C Loomans; J Alberola-Ila; S M Hedrick; C Murre
Journal:  Nat Immunol       Date:  2001-02       Impact factor: 25.606

8.  ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation.

Authors:  Jer-Yen Yang; Cong S Zong; Weiya Xia; Hirohito Yamaguchi; Qingqing Ding; Xiaoming Xie; Jing-Yu Lang; Chien-Chen Lai; Chun-Ju Chang; Wei-Chien Huang; Hsin Huang; Hsu-Ping Kuo; Dung-Fang Lee; Long-Yuan Li; Huang-Chun Lien; Xiaoyun Cheng; King-Jen Chang; Chwan-Deng Hsiao; Fuu-Jen Tsai; Chang-Hai Tsai; Aysegul A Sahin; William J Muller; Gordon B Mills; Dihua Yu; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Nat Cell Biol       Date:  2008-01-20       Impact factor: 28.824

9.  c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 signaling pathways have divergent roles in CD8(+) T cell-mediated antiviral immunity.

Authors:  Nathalie Arbour; Denise Naniche; Dirk Homann; Roger J Davis; Richard A Flavell; Michael B A Oldstone
Journal:  J Exp Med       Date:  2002-04-01       Impact factor: 14.307

10.  c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 have distinct roles in CD8(+) T cell activation.

Authors:  Dietrich Conze; Troy Krahl; Norman Kennedy; Linda Weiss; Joanne Lumsden; Patricia Hess; Richard A Flavell; Graham Le Gros; Roger J Davis; Mercedes Rincón
Journal:  J Exp Med       Date:  2002-04-01       Impact factor: 14.307

View more
  90 in total

1.  Single-cell mass cytometry of TCR signaling: amplification of small initial differences results in low ERK activation in NOD mice.

Authors:  Michael Mingueneau; Smita Krishnaswamy; Matthew H Spitzer; Sean C Bendall; Erica L Stone; Stephen M Hedrick; Dana Pe'er; Diane Mathis; Garry P Nolan; Christophe Benoist
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-31       Impact factor: 11.205

2.  HIV-1 infection abrogates CD8+ T cell mitogen-activated protein kinase signaling responses.

Authors:  Timothy Q Crawford; Lishomwa C Ndhlovu; Alice Tan; Alex Carvidi; Frederick M Hecht; Elizabeth Sinclair; Jason D Barbour
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

3.  Alternative splicing of Bim and Erk-mediated Bim(EL) phosphorylation are dispensable for hematopoietic homeostasis in vivo.

Authors:  C Clybouw; D Merino; T Nebl; F Masson; M Robati; L O'Reilly; A Hübner; R J Davis; A Strasser; P Bouillet
Journal:  Cell Death Differ       Date:  2012-01-13       Impact factor: 15.828

4.  ERK1 is important for Th2 differentiation and development of experimental asthma.

Authors:  Nicholas Goplen; Zunayet Karim; Lei Guo; Yonghua Zhuang; Hua Huang; Magdalena M Gorska; Erwin Gelfand; Gilles Pagés; Jacques Pouysségur; Rafeul Alam
Journal:  FASEB J       Date:  2012-01-18       Impact factor: 5.191

Review 5.  TCR signaling requirements for activating T cells and for generating memory.

Authors:  Dietmar Zehn; Carolyn King; Michael J Bevan; Ed Palmer
Journal:  Cell Mol Life Sci       Date:  2012-04-19       Impact factor: 9.261

Review 6.  The persistence of T cell memory.

Authors:  Mark A Daniels; Emma Teixeiro
Journal:  Cell Mol Life Sci       Date:  2010-04-04       Impact factor: 9.261

7.  Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.

Authors:  Christopher A Klebanoff; Joseph G Crompton; Anthony J Leonardi; Tori N Yamamoto; Smita S Chandran; Robert L Eil; Madhusudhanan Sukumar; Suman K Vodnala; Jinhui Hu; Yun Ji; David Clever; Mary A Black; Devikala Gurusamy; Michael J Kruhlak; Ping Jin; David F Stroncek; Luca Gattinoni; Steven A Feldman; Nicholas P Restifo
Journal:  JCI Insight       Date:  2017-12-07

Review 8.  Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development.

Authors:  Ralph E Parchment; James H Doroshow
Journal:  Semin Oncol       Date:  2016-07-26       Impact factor: 4.929

Review 9.  New insights into the regulation and function of serine/threonine kinases in T lymphocytes.

Authors:  Sharon A Matthews; Doreen A Cantrell
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

10.  Nuclear translocation of MEK1 triggers a complex T cell response through the corepressor silencing mediator of retinoid and thyroid hormone receptor.

Authors:  Lei Guo; Chaoyu Chen; Qiaoling Liang; Mohammad Zunayet Karim; Magdalena M Gorska; Rafeul Alam
Journal:  J Immunol       Date:  2012-12-05       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.